The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
NCT ID: NCT00868283
Last Updated: 2023-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1071 participants
INTERVENTIONAL
2006-09-30
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cerebrolysin
Cerebrolysin
30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
0.9% Saline Solution
0.9% Saline Solution
30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cerebrolysin
30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
0.9% Saline Solution
30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Focal neurological deficit
* Clinical diagnosis of acute hemispheric ischemic stroke
* CT or MRI results compatible with clinical diagnosis of acute hemispheric stroke
* NIH Stroke Scale Score between 6 and 22, both inclusive
* Functionally independent prior to stroke with a pre-stroke Rankin Score of 0 or 1
* Randomization and first treatment with the trial medication within 12h after stroke onset
* Informed consent given by the patient and/or the patient's legally acceptable representative
Exclusion Criteria
* Signs of herniation, increased intracranial pressure or likely etiology other than brain ischemia at baseline CT scan
* Patients with a substantial decrease of consciousness or alertness at the time of randomization, defined as score of 2 or more one of the NIH Stroke Scale questions 1a.
* Neurological signs and symptoms that improve rapidly during screening and are likely to resolve completely within 24h
* Severe coexisting systemic disease that significantly limits life expectancy
* Systolic blood pressure over 220 mmHg or diastolic blood pressure over 120 mmHg on repeated measurement (interval of 30 min) prior to study entry
* Severe congestive heart failure or presentation with acute myocardial infarction at study entry
* Epilepsy or epileptic seizures at onset of stroke
* Pre-existing disorders or conditions that would impair interpretation of neurological assessment (eg. severe dementia, severe psychiatric illnesses, etc).
* Concomitant treatment with other neuroprotective or nootropic drugs (e.g. piracetam, citicoline, investigational neuroprotective substances)
* Patients which cannot tolerate or have contraindication to aspirin or Cerebrolysin treatment
* Concomitant treatment with substances that have a dilative effect on blood vessels like naftidrofuryl, cinnarizine, flunarizine or nimodipine
* Pregnancy and lactation period; for women with child-bearing potential a negative pregnancy test is required
* Participation in a clinical trial with an investigational drug in the past 4 weeks
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Excel PharmaStudies, Inc.
INDUSTRY
idv Datenanalyse und Versuchsplanung
UNKNOWN
Ever Neuro Pharma GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philipp Novak, PhD
Role: STUDY_DIRECTOR
EVER Neuro Pharma
Zhen Hong, MD
Role: PRINCIPAL_INVESTIGATOR
Huashan Hospital, affiliated Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mudanjiang 1st people Hospital
Mudanjiang, Heilongjiang, China
Mudanjiang 2nd people Hospital
Mudanjiang, Heilongjiang, China
Anhui Shengli Hospital
Anhui, , China
Anshan hospital
Anshan, , China
Baotou Center Hospital
Baotou, , China
Third hospital, affiliated Neimenggu Medical University (Bao Gang hospital)
Baotou, , China
Beijing PLA General Hospital
Beijing, , China
First hospital, affiliated Peking University
Beijing, , China
Friendship Hospital, affiliated Capital Medical University
Beijing, , China
Peking Anzhen Hospital
Beijing, , China
Sino-Japanese Friendship Hospital
Beijing, , China
First hospital, affiliated Bethune Medical University
Changchun, , China
Second Hospital Affiliated Bethune Medical University
Changchun, , China
Xiangya Hospital, affiliated Hunan Medical University
Changsha, , China
Chengdu 2nd People's Hospital
Chengdu, , China
First Hospital, affiliated Huaxi Medical University
Chengdu, , China
Sichuan Province People's Hospital
Chengdu, , China
Second Hospital, affiliated Chongqing Med. University
Chongqing, , China
Dalian Center Hospital
Dalian, , China
Dalian third people Hospital
Dalian, , China
Second Hospital, affiliated Wenzhou Med. University
Dalian, , China
First hospital, affiliated Fujian Medical University
Fuzhou, , China
FuJian Shengli Hospital
Fuzhou, , China
First Hospital, affiliated Shantou Medical University
Guandong, , China
Guangzhou 2nd People's Hospital
Guangzhou, , China
Guangzhou red cross hospital
Guangzhou, , China
First Hospital, affiliated Medical college Zhejing University
Hangzhou, , China
The 4st Hospital affiliated Harbin Medical University
Harbin, , China
Second Hospital, affiliated Kunming Med. University
Kunming, , China
Yinchuan People's Hospital
Mudanjiang, , China
Nanjing PLA General Hospital
Nanjing, , China
Zhongda Hospital
Nanjing, , China
First Hospital, affiliated Qingdao Medical University
Qingdao, , China
Huashan Hospital, affiliated Fudan University
Shanghai, , China
Renji Hospital, affiliated Second Medical University
Shanghai, , China
Ruijin Hospital, affiliated Jiaotong University
Shanghai, , China
Shanghai 6th People's Hospital
Shanghai, , China
Xinhua hospital of Shanghai Jiaotong University School of Medicine
Shanghai, , China
Zhongshan Hospital, affiliated Fudan University
Shanghai, , China
Hebei Province People's Hospital
Shijiazhuang, , China
Tianjin First Medical Center
Tianjin, , China
Tianjin Union Medicine Centre
Tianjin, , China
Union Hospital, affiliated Huazhong science and technology University
Wuhan, , China
First hospital, affiliated NingXia Mededical University
Yinchuan, , China
First hospital, affiliated Henan Medical University
Zhengzhou, , China
Chinese University of Hong Kong
Hong Kong, , Hong Kong
Asan medical center
Seoul, , South Korea
East-west neo medical center
Seoul, , South Korea
Kyung-hee University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD; CASTA-Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia--CASTA. Int J Stroke. 2009 Oct;4(5):406-12. doi: 10.1111/j.1747-4949.2009.00340.x.
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012 Mar;43(3):630-6. doi: 10.1161/STROKEAHA.111.628537. Epub 2012 Jan 26.
Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Homberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018 Apr;39(4):629-640. doi: 10.1007/s10072-017-3214-0. Epub 2017 Dec 16.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EBE-CN-050823
Identifier Type: -
Identifier Source: org_study_id